{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T04:33:28Z","timestamp":1768797208534,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.pupt.2005.09.009","type":"journal-article","created":{"date-parts":[[2005,12,20]],"date-time":"2005-12-20T09:05:58Z","timestamp":1135069558000},"page":"20-29","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S1","title":["Pharmacologic characteristics of prulifloxacin"],"prefix":"10.1016","volume":"19","author":[{"given":"Maria Gabriella","family":"Matera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2005.09.009_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.5264\/eiyogakuzashi.61.161","article-title":"The history of the development and changes of quinolone antibacterial agents","volume":"38","author":"Takahashi","year":"2003","journal-title":"Yakushigaku Zasshi"},{"key":"10.1016\/j.pupt.2005.09.009_bib2","unstructured":"Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents, 2nd ed, vol. 3. Washington, DC: American Society for Microbiology; 1993."},{"key":"10.1016\/j.pupt.2005.09.009_bib3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1128\/AAC.38.2.163","article-title":"New quinolones and Gram-positive bacteria","volume":"38","author":"Piddock","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib4","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200464190-00005","article-title":"Prulifloxacin","volume":"64","author":"Keam","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2005.09.009_bib5","first-page":"882","article-title":"Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa","volume":"55","author":"Tani","year":"2002","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.pupt.2005.09.009_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/AAC.37.4.793","article-title":"Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone","volume":"37","author":"Yoshida","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib7","unstructured":"Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology, 7th ed, vol. 5. Washington, DC: American Society for Microbiology; 1999."},{"key":"10.1016\/j.pupt.2005.09.009_bib8","series-title":"Methods for general and molecular bacteriology","first-page":"248","article-title":"Growth measurement","author":"Koch","year":"1994"},{"key":"10.1016\/j.pupt.2005.09.009_bib9","unstructured":"National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Tentative guideline M26-T. National Committee for Clinical Laboratory Standards, Villanova, PA, 1992."},{"key":"10.1016\/j.pupt.2005.09.009_bib10","unstructured":"National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000."},{"key":"10.1016\/j.pupt.2005.09.009_bib11","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1128\/AAC.35.12.2490","article-title":"In vitro antibacterial activity of a new quinolone, NM394","volume":"35","author":"Ozaki","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib12","first-page":"778","article-title":"In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone","volume":"55","author":"Araake","year":"2002","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.pupt.2005.09.009_bib13","first-page":"593","article-title":"In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC","volume":"53","author":"Inoue","year":"2000","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.pupt.2005.09.009_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10096-002-0709-1","article-title":"In vitro activity of the active metabolite of prulifloxacin (PUFX) compared with six other fluoroquinolones","volume":"21","author":"Prats","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.pupt.2005.09.009_bib15","first-page":"799","article-title":"In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates","volume":"38","author":"Montanari","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib16","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1128\/JCM.40.8.2746-2749.2002","article-title":"Vaginal Lactobacillus flora of healthy Swedish women","volume":"40","author":"Vasquez","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.pupt.2005.09.009_bib17","first-page":"43","article-title":"\u201cNot trash again!\u201d. Women experience of post-antibiotic vulvovaginitis","volume":"179","author":"Pirotta","year":"2003","journal-title":"MJA"},{"key":"10.1016\/j.pupt.2005.09.009_bib18","unstructured":"Tempera A. In vitro antibacterial activity of prulifloxacin against clinically isolated vaginal lactobacillus strains. Rome: Angelini\u2014ACRAF S.p.A., 2005 (data on file)."},{"key":"10.1016\/j.pupt.2005.09.009_bib19","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1128\/AAC.38.9.2065","article-title":"Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology","volume":"38","author":"Pankuch","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/27.4.399","article-title":"Mechanism of quinolone uptake into bacterial cells","volume":"27","author":"Piddock","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/jac\/39.5.617","article-title":"The effect of quinolones on the intracellular killing of Staphylococcus aureus in neutrophil granulocytes","volume":"39","author":"Nielsen","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib22","first-page":"791","article-title":"In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin","volume":"55","author":"Shimizu","year":"2002","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.pupt.2005.09.009_bib23","unstructured":"Broccali GP, Visconti M. Evaluation of the postantibiotic effect of AF 3013 in comparison to ciprofloxacin. Rome: Angelini\u2014ACRAF S.p.A., 1995 (data on file)."},{"key":"10.1016\/j.pupt.2005.09.009_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/AAC.40.2.314","article-title":"Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia","volume":"40","author":"Edelstein","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/jac\/32.2.279","article-title":"Intraphagocytic bioactivity of lomefloxacin against Pseudomonas aeruginosa","volume":"32","author":"Cant\u00f3n","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/AAC.41.2.274","article-title":"Uptake and intracellular activity of trovafloxacin in human phagocytes and tissue-cultured epithelial cells","volume":"41","author":"Pascual","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib27","first-page":"241","article-title":"Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages","volume":"46","author":"Carlier","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.40.3.739","article-title":"Uptake and intracellular activity\u2019 of NM394, a new quinolone, in human polymorphonuclear leukocytes","volume":"40","author":"Ozaki","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jac\/46.2.241","article-title":"Influence of a new fluoroquinolone, AF3013 (the active metabolite of prulifloxacin), on macrophage functions against Klebsiella pneumoniae: an in vitro comparison with prulifloxacin","volume":"46","author":"Tullio","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib30","first-page":"1","article-title":"Cellular uptake and intraphagocytic activity of the new fluoroquinolone AF3013 against Klebsiella pneumoniae","volume":"25","author":"Tullio","year":"1999","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.pupt.2005.09.009_bib31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijantimicag.2003.07.006","article-title":"Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils","volume":"23","author":"Reato","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.pupt.2005.09.009_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/313677","article-title":"New uses for new and old quinolones and the challenge of resistance","volume":"30","author":"Hooper","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pupt.2005.09.009_bib33","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.35.12.2496","article-title":"In vivo evaluation of NM441, a new thiazeto-quinoline derivative","volume":"35","author":"Ozaki","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000007086","article-title":"In vivo antibacterial activity of a prodrug of NM394, a thiazetoquinoline carboxylic acid derivative","volume":"44","author":"Ozaki","year":"1998","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pupt.2005.09.009_bib35","first-page":"1169","article-title":"Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice","volume":"46","author":"Tomii","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pupt.2005.09.009_bib36","first-page":"355","article-title":"Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent","volume":"26","author":"Tougou","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pupt.2005.09.009_bib37","first-page":"276","article-title":"Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration","volume":"47","author":"Okuyama","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pupt.2005.09.009_bib38","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/j.1552-4604.1994.tb04007.x","article-title":"Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers","volume":"34","author":"Nakashima","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pupt.2005.09.009_bib39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2165\/00003495-199500492-00091","article-title":"Penetration of NM441, a new quinolone, into human bile and gallbladder tissue","volume":"49","author":"Tanimura","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2005.09.009_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00003495-199500492-00087","article-title":"NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients","volume":"49","author":"Mikamo","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.pupt.2005.09.009_bib41","first-page":"293","article-title":"Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys","volume":"47","author":"Okuyama","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pupt.2005.09.009_bib42","first-page":"201","article-title":"Pharmacokinetics and tolerability of prulifloxacin after single oral administration","volume":"53","author":"Picollo","year":"2003","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pupt.2005.09.009_bib43","first-page":"285","article-title":"Pharmacokinetics of prulifloxacin. 2nd communication: pharmacokinetics and effect on hepatic drug-metabolizing enzyme activities after repeated administration and transfer into fetus and milk after a single administration in rats","volume":"47","author":"Okuyama","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pupt.2005.09.009_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000057841","article-title":"Evidence of different profiles of side effects and drug\u2013drug interactions among the quinolones\u2014the pharmacokinetic standpoint","volume":"47","author":"Lode","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.pupt.2005.09.009_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00044011-199816050-00006","article-title":"Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers","volume":"16","author":"Fattore","year":"1998","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.pupt.2005.09.009_bib46","first-page":"1019","article-title":"Ciprofloxacin","volume":"51","author":"Davis","year":"1996","journal-title":"An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs"},{"key":"10.1016\/j.pupt.2005.09.009_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2131\/jts.21.SupplementI_71","article-title":"A 4-week oral toxicity study of prulifloxacin (NM441) in dogs followed by a 4-week recovery test","volume":"21","author":"Oda","year":"1996","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.pupt.2005.09.009_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2131\/jts.21.SupplementI_89","article-title":"A 13-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 5-week recovery test","volume":"21","author":"Ishibashi","year":"1996","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.pupt.2005.09.009_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2131\/jts.21.SupplementI_207","article-title":"Reproductive and developmental toxicity studies of prulifloxacin (NM441)(3)\u2014a teratogenicity study in rabbits by oral administration","volume":"21","author":"Morinaga","year":"1996","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.pupt.2005.09.009_bib50","first-page":"113","article-title":"General pharmacological studies of NM441. (1). Effects on central and peripheral nervous systems, gastrointestinal tract and smooth muscle","volume":"44","author":"Kura","year":"1996","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib51","first-page":"129","article-title":"General pharmacological studies of NM441. (2). Effects on respiratory and cardiovascular systems, renal function and others","volume":"44","author":"Kura","year":"1996","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.pupt.2005.09.009_bib52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0014-2999(03)02180-0","article-title":"Prulifloxacin: in vitro (ERG) and in vivo (conscious dog) assessment of cardiac risk","volume":"477","author":"Lacroix","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pupt.2005.09.009_bib53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2131\/jts.29.63","article-title":"Comparative assessment of prulifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia","volume":"29","author":"Akita","year":"2004","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.pupt.2005.09.009_bib54","first-page":"102","article-title":"Convulsant effects of NM441, e prodrug type antibacterial agent of the quinolone class","volume":"44","author":"Ukai","year":"1996","journal-title":"Jpn J Chemother"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553905001483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553905001483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T09:22:17Z","timestamp":1554974537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553905001483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":54,"alternative-id":["S1094553905001483"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2005.09.009","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}